References

Volkow, Nora D. “Cannabidiol: Barriers to Research and Potential Medical Benefits.” Drug Caucus Hearing on Barriers to Cannabidiol Research, United States Senate Caucus on International Narcotics Control. June 24, 2015 Retrieved from https://www.drugabuse.gov/about-nida/legislativeactivities/testimony-to-congress/2016/biologypotential-therapeutic-effects-cannabidiol

Ligresti et al. “Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.” J Pharmacol Exp Ther 318.3 (2006): 1375-1387.

Massi et al. “Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.” J Pharmacol Exp Ther 308.3 (2004): 838-845.

McAllister et al. “The Antitumor Activity of Plan tDerived Non-Psychoactive Cannabinoids.” J Neuroimmune Pharmacol 10.2 (2015): 255-267.

Esposito et al. “The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/betacatenin pathway rescue in PC12 cells.” J Mol Med (Berl) 84.3 (2006): 253-258.

Martín-Moreno et al. “Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease.” Mol Pharmacol 79.6 (2011): 964-973.

Iuvone et al. “Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells.” J Neurochem 89.1 (2004): 134-141.

Pazos et al. “Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5-HT1A and CB2 receptors.” Neuropharmacology 71 (2013): 282-291.

Hampson et al. “Cannabidiol and (-)Delta9tetrahydrocannabinol are neuroprotective antioxidants.” Proc Natl Acad Sci USA 95.14 (1998): 8268-8273.

Pryce et al. “Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.” J Neuroimmune Pharmacol 10.2 (2015): 281-292.

García-Arencibia et al. “Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties.” Brain Res 1134.1 (2007): 162-170.

Schier et al. “Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.” Rev Bras Psiquiatr, 34.1 (2012): 104-110.

Zuardi et al. “Effect of cannabidiol on plasma prolactin, growth hormone, and cortisol in human volunteers.” Braz J of Med and Biol Res 26.2 (1993): 213–217.

Malfait et al. “The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.” Proc Natl Acad Sci USA 97.17 (2000): 9561-9566.

Costa et al. “Oral anti-inflammatory activity of cannabidiol, a nonpsychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw.” Naunyn Schmiedebergs Arch Pharmacol 369.3 (2004): 294299.

Di Marzo, Vincenzo and Diego Centonze. ‘Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.” CNS Neurosci Ther. 21.3 (2015): 215-21.

Flachenecker et al. “Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice– results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.” Eur Neurol. 71.5-6 (2014): 271-279.

Porter, Brenda E. and Catherine Jacobson “Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.” Epilepsy & Behavior 29 (2013) 574–577

Cunha et al. “Chronic administration of cannabidiol to healthy volunteers and epileptic patients.” Pharmacology 21.3 (1980): 175-185.

Parker et al. “Cannabidiol, a nonpsychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats.” Neuroreport. 13.5 (2002): 567-570.